Elizabeth Devlin - Century Therapeutics VP Development
| IPSC Stock | USD 1.76 0.01 0.57% |
VP
Elizabeth Devlin is VP Development of Century Therapeutics
| Address | 25 North 38th Street, Philadelphia, PA, United States, 19104 |
| Phone | 267 817 5790 |
| Web | https://www.centurytx.com |
Century Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0447) % which means that it has lost $0.0447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1424) %, meaning that it created substantial loss on money invested by shareholders. Century Therapeutics' management efficiency ratios could be used to measure how well Century Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2026, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.75. At present, Century Therapeutics' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 365.6 M, whereas Other Assets are forecasted to decline to 0.86.Similar Executives
| Found 6 records | VP Age | ||
| George Zavoico | Cue Biopharma | N/A | |
| MSE JD | Cue Biopharma | 69 | |
| Michael JD | Karyopharm Therapeutics | 48 | |
| Brendan Strong | Karyopharm Therapeutics | N/A | |
| Kristin Abate | Karyopharm Therapeutics | N/A | |
| Reshma MD | Karyopharm Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0447 |
Century Therapeutics Leadership Team
Elected by the shareholders, the Century Therapeutics' board of directors comprises two types of representatives: Century Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Century. The board's role is to monitor Century Therapeutics' management team and ensure that shareholders' interests are well served. Century Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Century Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Diem, Chief Officer | ||
| Morgan Conn, Chief Officer | ||
| Michael Naso, Senior Engineering | ||
| Nick MD, Senior Development | ||
| Kenneth JD, Head Compliance | ||
| Chad Cowan, Chief Officer | ||
| Elizabeth Devlin, VP Development | ||
| PharmD MBA, CEO President | ||
| Adrienne Farid, Chief Development | ||
| Shane Williams, Chief Officer | ||
| Gregory Russotti, Chief Officer | ||
| Douglas CPA, Principal Operations | ||
| Mark Wallet, Head VP | ||
| Megan Bilson, Chief Officer | ||
| Luis Borges, Chief Officer | ||
| Michael MD, Chief Officer | ||
| Osvaldo Flores, CEO Pres | ||
| Hyam MD, President Development | ||
| Katja Buhrer, Head SVP |
Century Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Century Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0447 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 65.6 M | ||||
| Shares Outstanding | 87.41 M | ||||
| Shares Owned By Insiders | 25.93 % | ||||
| Shares Owned By Institutions | 74.07 % | ||||
| Number Of Shares Shorted | 3.39 M | ||||
| Price To Earning | 86.08 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Will Biotechnology sector continue expanding? Could Century diversify its offerings? Factors like these will boost the valuation of Century Therapeutics. Market participants price Century higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Century Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 126.677 | Return On Assets | Return On Equity |
Investors evaluate Century Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Century Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Century Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Century Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.